|
||
| Gilenya News Channel |  |
|
|
|||||
|
|||||
|
|||||
| MS NEWS ARCHIVES: by week | |||||
| July 2013 | |||||
| September 2013 | |||||
| October 2013 | |||||
| June 2014 | |||||
| July 2014 | |||||
| January 2015 | |||||
| February 2015 | |||||
| March 2015 | |||||
| April 2015 | |||||
| May 2015 | |||||
| July 2015 | |||||
| March 2016 | |||||
| April 2016 | |||||
| May 2016 | |||||
| June 2016 | |||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | |||||
 |
|||||
| |||||
| |||||
 Click to view 1280 MS Walk photos! | |||||
|
|||||
|
|||||
|
|||||
Monday
Positive Results Published on Clinical Trials of Oral FTY720 (Fingolimod) for Relapsing MS -- Novartis Applies to FDA and European Regulatory Agency f
( Posted by Desinie Smith)
Jan 20, 2010
Positive Results Published on Clinical Trials of Oral FTY720 (Fingolimod) for Relapsing MS -- Novartis Applies to FDA and European Regulatory Agency for Approval
Positive results from two large-scale phase III clinical trials of oral fingolimod (FTY720) have been published showing it significantly reduced multiple sclerosis relapse rates, and one of the trials also suggested it could slow the progression of disability. The sponsor, Novartis International AG, has announced that it applied for marketing approval in the U.S. and European Union in December 2009. There are currently no approved oral disease-modifying therapies for MS. The papers were published early online in the New England Journal of Medicine (links one and two) on January 20, 2010, along with a separate paper that describes results from a clinical trial of another orally administered experimental therapy, cladribine.
Read the rest of the article on the NMSS's website click here.
Jan 20, 2010
Positive Results Published on Clinical Trials of Oral FTY720 (Fingolimod) for Relapsing MS -- Novartis Applies to FDA and European Regulatory Agency for Approval
Positive results from two large-scale phase III clinical trials of oral fingolimod (FTY720) have been published showing it significantly reduced multiple sclerosis relapse rates, and one of the trials also suggested it could slow the progression of disability. The sponsor, Novartis International AG, has announced that it applied for marketing approval in the U.S. and European Union in December 2009. There are currently no approved oral disease-modifying therapies for MS. The papers were published early online in the New England Journal of Medicine (links one and two) on January 20, 2010, along with a separate paper that describes results from a clinical trial of another orally administered experimental therapy, cladribine.
Read the rest of the article on the NMSS's website click here.